Combination immunotherapy: Where do we go from here? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12

AUTHORS

Abigail E. Overacre, Sema Kurtulus, Mario Sznol, Drew M. Pardoll, Ana Anderson, Dario A. A. Vignali

ABSTRACT

The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014. More... »

PAGES

38

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z

DOI

http://dx.doi.org/10.1186/s40425-015-0083-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040993290


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh", 
          "id": "https://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Overacre", 
        "givenName": "Abigail E.", 
        "id": "sg:person.01112462306.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112462306.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Harvard University", 
          "id": "https://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kurtulus", 
        "givenName": "Sema", 
        "id": "sg:person.01337707220.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337707220.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Johns Hopkins University", 
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": [
            "Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pardoll", 
        "givenName": "Drew M.", 
        "id": "sg:person.012740423777.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012740423777.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Harvard University", 
          "id": "https://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women\u2019s Hospital and Harvard Medical School, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anderson", 
        "givenName": "Ana", 
        "id": "sg:person.0676714763.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676714763.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Pittsburgh", 
          "id": "https://www.grid.ac/institutes/grid.21925.3d", 
          "name": [
            "Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vignali", 
        "givenName": "Dario A. A.", 
        "id": "sg:person.07642160524.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07642160524.60"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2015-12", 
    "datePublishedReg": "2015-12-01", 
    "description": "The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against \u201cimmunologically inert\u201d tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1186/s40425-015-0083-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "3"
      }
    ], 
    "name": "Combination immunotherapy: Where do we go from here?", 
    "pagination": "38", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c3476b9c61aa26999757a6074784a1608043df32e48e970bb8601b19aa82b53b"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-015-0083-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040993290"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-015-0083-z", 
      "https://app.dimensions.ai/details/publication/pub.1040993290"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54338_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-015-0083-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-015-0083-z'


 

This table displays all metadata directly associated to this object as RDF triples.

104 TRIPLES      20 PREDICATES      27 URIs      19 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-015-0083-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nd76f6976ea5b4a9c8b1d44979fffa6ba
4 schema:datePublished 2015-12
5 schema:datePublishedReg 2015-12-01
6 schema:description The remarkable clinical success of cancer immunotherapies targeting the checkpoint receptors CTLA-4 and PD-1 has generated considerable excitement and emboldened efforts to build on this important foundation. Research efforts are now focused on understanding the mechanism of action of these immunotherapies, identifying new inhibitory mechanisms that could be targeted to achieve responses in patients with refractory cancers, and developing approaches that might exhibit efficacy against “immunologically inert” tumors. The outstanding challenges in moving forward are developing reliable strategies for determining which patients will respond optimally to a given immunotherapy, and what combination of immunotherapies and conventional therapies will prove beneficial against each tumor type. These issues were discussed in a one-day workshop at the SITC meeting in November 2014.
7 schema:genre non_research_article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf N0a85f374eca24f1190e9138f393d45a0
11 N11b36c72fda84e018acbec62ef7ca585
12 sg:journal.1049249
13 schema:name Combination immunotherapy: Where do we go from here?
14 schema:pagination 38
15 schema:productId N65f03d44f321485296cb91a100a2a455
16 N8545c16a95ad4c96b8dfb7569db8bc25
17 N874feb2a6f6b46a685f0791cc0d12e5a
18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040993290
19 https://doi.org/10.1186/s40425-015-0083-z
20 schema:sdDatePublished 2019-04-11T10:21
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher N8e18f773d48848f7a1f3c447065b1a3a
23 schema:url https://link.springer.com/10.1186%2Fs40425-015-0083-z
24 sgo:license sg:explorer/license/
25 sgo:sdDataset articles
26 rdf:type schema:ScholarlyArticle
27 N0a85f374eca24f1190e9138f393d45a0 schema:volumeNumber 3
28 rdf:type schema:PublicationVolume
29 N11add6563ead4df18cfe02d28c15ef7a rdf:first sg:person.07642160524.60
30 rdf:rest rdf:nil
31 N11b36c72fda84e018acbec62ef7ca585 schema:issueNumber 1
32 rdf:type schema:PublicationIssue
33 N448644b421404a448ec8d0c9f6a64e41 rdf:first sg:person.012740423777.12
34 rdf:rest N6328b704338a4714a8ecb1e0afe72f43
35 N6328b704338a4714a8ecb1e0afe72f43 rdf:first sg:person.0676714763.05
36 rdf:rest N11add6563ead4df18cfe02d28c15ef7a
37 N65f03d44f321485296cb91a100a2a455 schema:name readcube_id
38 schema:value c3476b9c61aa26999757a6074784a1608043df32e48e970bb8601b19aa82b53b
39 rdf:type schema:PropertyValue
40 N6be4d14ecc6c47be8297712c8c7cc04d rdf:first sg:person.0706626451.72
41 rdf:rest N448644b421404a448ec8d0c9f6a64e41
42 N8545c16a95ad4c96b8dfb7569db8bc25 schema:name doi
43 schema:value 10.1186/s40425-015-0083-z
44 rdf:type schema:PropertyValue
45 N874feb2a6f6b46a685f0791cc0d12e5a schema:name dimensions_id
46 schema:value pub.1040993290
47 rdf:type schema:PropertyValue
48 N8e18f773d48848f7a1f3c447065b1a3a schema:name Springer Nature - SN SciGraph project
49 rdf:type schema:Organization
50 Nc9b0ab5e03744d4ea0ecdb3f041c9d09 rdf:first sg:person.01337707220.24
51 rdf:rest N6be4d14ecc6c47be8297712c8c7cc04d
52 Nd76f6976ea5b4a9c8b1d44979fffa6ba rdf:first sg:person.01112462306.15
53 rdf:rest Nc9b0ab5e03744d4ea0ecdb3f041c9d09
54 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
55 schema:name Medical and Health Sciences
56 rdf:type schema:DefinedTerm
57 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
58 schema:name Oncology and Carcinogenesis
59 rdf:type schema:DefinedTerm
60 sg:journal.1049249 schema:issn 2051-1426
61 schema:name Journal for ImmunoTherapy of Cancer
62 rdf:type schema:Periodical
63 sg:person.01112462306.15 schema:affiliation https://www.grid.ac/institutes/grid.21925.3d
64 schema:familyName Overacre
65 schema:givenName Abigail E.
66 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112462306.15
67 rdf:type schema:Person
68 sg:person.012740423777.12 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
69 schema:familyName Pardoll
70 schema:givenName Drew M.
71 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012740423777.12
72 rdf:type schema:Person
73 sg:person.01337707220.24 schema:affiliation https://www.grid.ac/institutes/grid.38142.3c
74 schema:familyName Kurtulus
75 schema:givenName Sema
76 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337707220.24
77 rdf:type schema:Person
78 sg:person.0676714763.05 schema:affiliation https://www.grid.ac/institutes/grid.38142.3c
79 schema:familyName Anderson
80 schema:givenName Ana
81 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676714763.05
82 rdf:type schema:Person
83 sg:person.0706626451.72 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
84 schema:familyName Sznol
85 schema:givenName Mario
86 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
87 rdf:type schema:Person
88 sg:person.07642160524.60 schema:affiliation https://www.grid.ac/institutes/grid.21925.3d
89 schema:familyName Vignali
90 schema:givenName Dario A. A.
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07642160524.60
92 rdf:type schema:Person
93 https://www.grid.ac/institutes/grid.21107.35 schema:alternateName Johns Hopkins University
94 schema:name Division of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 21287, Baltimore, MD, USA
95 rdf:type schema:Organization
96 https://www.grid.ac/institutes/grid.21925.3d schema:alternateName University of Pittsburgh
97 schema:name Department of Immunology, University of Pittsburgh, 15213, Pittsburgh, PA, USA
98 rdf:type schema:Organization
99 https://www.grid.ac/institutes/grid.38142.3c schema:alternateName Harvard University
100 schema:name Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, 02115, Boston, MA, USA
101 rdf:type schema:Organization
102 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
103 schema:name Division of Medical Oncology, Yale Comprehensive Cancer Center, Yale University, 06250, New Haven, CT, USA
104 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...